ReviewCurrent psychiatry reports2010
Assessment of pharmacotherapy for negative symptoms of schizophrenia.
Review in Current psychiatry reports, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07759895 (Combination Therapy of Deferiprone and N-Acetylcysteine for Treating Negative Symptoms in Schizophrenia), which is not on this map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Combination Therapy of Deferiprone and N-Acetylcysteine for Treating Negative Symptoms in Schizophrenia
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Healing potential of art therapy: a narrative review of neuro-psycho-cultural mechanisms in mental health.Frontiers in psychology · 2025Pooled it
- A double-blind, placebo controlled, randomized trial of riluzole as an adjunct to risperidone for treatment of negative symptoms in patients with chronic schizophrenia.Psychopharmacology · 2014Trial
- Ginkgo Biloba as a niche theme cognitive enhancer agent, 1420 dokumen of Scopus database. A bibliometric study from 1988 to 2024.F1000Research · 2025Article
- miRNA cargo in circulating vesicles from neurons is altered in individuals with schizophrenia and associated with severe disease.Science advances · 2023Article
- Evaluation of a new intrinsic and extrinsic motivation scale in youth with psychosis spectrum symptoms.Comprehensive psychiatry · 2023Article
- Relationship of ventral striatum activation during effort discounting to clinical amotivation severity in schizophrenia.NPJ schizophrenia · 2021Article
- Selective adrenergic alpha2C receptor antagonist ameliorates acute phencyclidine-induced schizophrenia-like social interaction deficits in rats.Psychopharmacology · 2019Article
- A Critical Period for the Development of Schizophrenia-Like Pathology by Aberrant Postnatal Neurogenesis.Frontiers in neuroscience · 2019Article
- Effectiveness of Prescription-Based CNS Stimulants on Hospitalization in Patients With Schizophrenia: A Nation-Wide Register Study.Schizophrenia bulletin · 2018Article
- Anxiety does not contribute to social withdrawal in the subchronic phencyclidine rat model of schizophrenia.Behavioural pharmacology · 2017Article
- Neuroprotection in Schizophrenia and Its Therapeutic Implications.Psychiatry investigation · 2017Review
- Plastic and Neuroprotective Mechanisms Involved in the Therapeutic Effects of Cannabidiol in Psychiatric Disorders.Frontiers in pharmacology · 2017Review
- Cannabidiol as a Potential New Type of an Antipsychotic. A Critical Review of the Evidence.Frontiers in pharmacology · 2016Review
- Efficacy of a glycine transporter 1 inhibitor TASP0315003 in animal models of cognitive dysfunction and negative symptoms of schizophrenia.Psychopharmacology · 2015Article
- Striatal dopamine receptor plasticity in neurotensin deficient mice.Behavioural brain research · 2015Article
- Amotivation in schizophrenia: integrated assessment with behavioral, clinical, and imaging measures.Schizophrenia bulletin · 2014Article
- The impact of second-generation antipsychotic adherence on positive and negative symptoms in recent-onset schizophrenia.Schizophrenia research · 2014Article
- Phencyclidine-induced social withdrawal results from deficient stimulation of cannabinoid CB₁ receptors: implications for schizophrenia.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2013Article
- Clarifying delirium management: practical, evidenced-based, expert recommendations for clinical practice.Journal of palliative medicine · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Negative symptoms in schizophrenia include diminished ability to communicate, motivate, and socialize as potentially debilitating aspects of the illness that are associated with long-term impairment. Despite such burden, the domain has been underrepresented in drug development and treatment research. In this article, we review research regarding pharmacotherapy for negative symptoms, with a focus on studies published during the past 2 years. Clearly positive studies were limited to N-methyl-D-aspartate agonists, while antipsychotics and antidepressants did not show substantial benefit, and cognitive enhancers have yielded mixed results. Proof-of-concept studies of other agents such as minocycline and omega fatty acids yielded promising, albeit preliminary findings that warrant replication. Study outcomes and designs are discussed along with implications for future research.
Indexed as
Identifiers
20821286What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.